Document is current
Any future updates will be listed below
-
Authors
Nagarajah, James
Kim, Hyun
Nordquist, Luke
Prasad, Vikas
Scott, Nathaniel
Stevens, Daniel
Fongenie, Benjamin
Osborne, Joseph
-
Funding
Funding for this research was provided by:
Blue Earth Therapeutics (N/A)
- License Information
-
More Information
Article History
Received: 7 February 2025
Accepted: 23 April 2025
First Online: 6 May 2025
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and the International Council on Harmonisation Guidelines for Good Clinical Practice. The protocol was approved by each investigating site’s Independent Ethics Committee prior to initiation.
: Written informed consent was obtained from all individual participants included in the study.
: James Nagarajah reports research grants from Novartis and ABX. He has provided consulting/teaching services for Novartis, ITM, and Bayer. Hyun Kim provides consulting services for Novartis. Luke Nordquist has no relevant financial or non-financial interests to disclose. Vikas Prasad reports personal fees, reimbursement of travel expenses advisory board participation for Curium, Telix, RayzeBio, Lantheus, Cellectar, Lilly. Nathaniel Scott, Daniel Stevens, and Benjamin Fongenie are employees of Blue Earth Therapeutics Ltd. Joseph Osborne has provided consulting/teaching services for Siemens Healthineers.
